FDA Grants IND of ARTEMIS™ T cell Platform To Enhance CAR-T Cancer Therapies Without Cytokine Storm – MedicalResearch.com (blog)
|
FDA Grants IND of ARTEMIS™ T cell Platform To Enhance CAR-T Cancer Therapies Without Cytokine Storm
MedicalResearch.com (blog) ET190L1-ARTEMISTM utilizes Eureka's proprietary ARTEMISTM T cell receptor platform and proprietary human anti- CD19 binder to target CD19-positive malignancies. In preclinical studies, ET190L1-ARTEMISTM matched the cancer killing potency of current CAR … |
